Patients with atrial fibrillation who survive an intracranial hemorrhage may benefit from restarting oral anticoagulation therapy, according to results of a Danish cohort study presented at the 2016 European Society of Cardiology (ESC) congress.

Investigators found that patients who restarted oral anticoagulation therapy had better outcomes, including reduced risk of ischemic stroke and all-cause mortality.

Peter Brønnum Nielsen, PhD, FESC, of Aalborg University Hospital in Denmark and Gregory YH Lip, MD, FRCP of University of Birmingham Centre for Cardiovascular Sciences in the United Kingdom, discuss their findings with European Heart Journal editor-in-chief, Thomas Lüscher at the ESC congress in Rome, Italy.


Continue Reading

Reference

Nielsen PB, Larsen TB, Skjøth, F, Lip GYH. Outcomes associated with oral anticoagulant treatment post hemorrhagic stroke or traumatic intracranial bleeding: a nationwide cohort study on atrial fibrillation patients. Presented at European Society of Cardiology Congress. August 27-31, 2016; Rome, Italy.